Drug Profile

PHOX 2B

Alternative Names: PHOX-2-B; PHOX2B PC-CAR T

Latest Information Update: 04 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Myrio Therapeutics
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies; Peptides
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Cancer; Neuroblastoma

Most Recent Events

16 Jun 2025 Preclinical trials in Cancer in Australia (Parenteral) prior to June 2025 (Myrio Therapeutics pipeline, June 2025)
16 Jun 2025 Preclinical trials in Neuroblastoma in Australia (Parenteral) prior to June 2025 (Myrio Therapeutics pipeline, June 2025)
16 Jun 2025 US FDA approves IND application for PHOX 2B in Neuroblastoma

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com